Chordate Medical

Bergs Securities acted as sole manager and bookrunner in the SEK 18m rights issue in Chordate Medical

Chordate Medical is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East.